Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. Issue 12 (15th October 2019)

• Record Type: Journal Article
• Authors: Mellors, Patrick W.; Binder, Moritz; Buadi, Francis K.; Lacy, Martha Q.; Gertz, Morie A.; Dispenzieri, Angela; Hayman, Suzanne R.; Kapoor, Prashant; Gonsalves, Wilson I.; Hwa, Yi L.; Fonder, Amie; Hobbs, Miriam; Kourelis, Taxiarchis; Warsame, Rahma; Zeldenrust, Steven R.; Lust, John A.; Leung, Nelson; Go, Ronald S.; Kyle, Robert A.; Rajkumar, S. Vincent; Kumar, Shaji K.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 12(2019)
• Page Start: 2960
• Page End: 2967
• Publication Date: 2019-10-15
• Subjects: Multiple myeloma -- thrombocytopenia -- prognosis -- survival -- response; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1613536
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: The prognostic significance of novel agent-induced thrombocytopenia in newly diagnosed multiple myeloma (MM) is unknown. We identified 665 newly diagnosed patients receiving proteasome inhibitors and/or immunomodulators with pretreatment platelet counts ≥100, 000/µL. Median progression-free survival (PFS) was 1.88 years (95% CI 1.48–2.38) for patients who developed treatment-related thrombocytopenia (<100, 000/µL) within sixty days of initiation of first-line therapy, compared to 2.64 years (95% CI 2.39–2.78) in patients who did not ( p = .042), while median overall survival (OS) was 5.70 years (95% CI 3.02–9.00) and 8.43 years (95% CI 6.62–9.17), respectively ( p = .030). Platelet count reduction >70% from pretreatment baseline was similarly predictive of inferior PFS and OS. This is the first study to demonstrate the predictive and prognostic value of treatment-related thrombocytopenia in newly diagnosed MM.